Comparison of anti-spike IgG, anti-spike IgA levels and neutralizing antibody activity induced by CoronaVac and BNT162b2 vaccines in patients with inflammatory rheumatic diseases receiving immunosuppressive therapy

Autor: Fulya Cosan, Ozlem Unay Demirel, Demet Yalcin, Muhammed Mert Sonkaya, Isilsu Ezgi Uluisik, Olida Cecen, Yavuz Furuncuoglu, Deniz Maktav Celikmen, Osman Kara, Erkan Ceylan, Timucin Avsar
Jazyk: angličtina
Rok vydání: 2023
Předmět:
Zdroj: BMC Rheumatology, Vol 7, Iss 1, Pp 1-17 (2023)
Druh dokumentu: article
ISSN: 2520-1026
DOI: 10.1186/s41927-023-00342-x
Popis: Abstract Background The importance of COVID-19 vaccination for patients on immunosuppressive (IS) medication has increased due to the high risk of severe disease or mortality. Different vaccines have varying efficacy rates against symptomatic COVID-19, ranging from 46.8% to 95%. The objective of this study was to examine the differences in anti-Spike IgG, anti-Spike IgA, and neutralizing antibody (NAb) activity between the inactive CoronaVac vaccine and the mRNA-based BNT162b2 vaccine in IS patients. Method A total of 441 volunteers, including 104 IS patients, 263 healthy controls (HC), who received two doses of CoronaVac or BNT162b2, and 74 unvaccinated patients with a history of SARS-CoV-2 infection, were included in the study. Anti-spike IgG, IgA, and NAb activity were investigated. Results Immunogenicity with BNT162b2 was higher than with CoronaVac, but in IS groups, it was lower than HC (CoronaVac-IS: 79.3%, CoronaVac-HC: 96.5%, p
Databáze: Directory of Open Access Journals
Externí odkaz: